GUOQUAN (02517): Shi Kangping serves as a member of the Compensation Committee.
Guoquan (02517) announced that Mr. Shi Kangping, an independent non-executive director of the company, will no longer serve as a member of the nomination committee of the company, and will be replaced by Ms. Yu Fangjin as a member of the remuneration committee. Ms. Yu Fangjin, an independent non-executive director of the company, will no longer serve as a member of the remuneration committee of the company, and will be replaced by Mr. Shi Kangping as a member of the nomination committee. The above-mentioned adjustments will take effect from April 2, 2026.
GUOQUAN (02517) announced that Mr. Shi Kangping, an independent non-executive director of the company, will no longer serve as a member of the nomination committee of the company. Ms. Yu Fangjin will replace him as a member of the remuneration committee.
Ms. Yu Fangjin, an independent non-executive director of the company, will no longer serve as a member of the remuneration committee and will instead replace Mr. Shi Kangping as a member of the nomination committee. These adjustments will be effective from April 2, 2026.
Related Articles
HYGEIA HEALTH (06078) repurchased 2200 shares for HK$26,600 on April 2nd.
For months, the academic community in the United States has been amazed: Peg Bio (02565) new drug CR059 tops ADA, monthly/quarterly dosing opens a new era in the treatment of metabolic diseases.
Asia Cuanon Technology (603378.SH): Focused Fund plans to reduce its holdings by no more than 1%.
HYGEIA HEALTH (06078) repurchased 2200 shares for HK$26,600 on April 2nd.
For months, the academic community in the United States has been amazed: Peg Bio (02565) new drug CR059 tops ADA, monthly/quarterly dosing opens a new era in the treatment of metabolic diseases.
Asia Cuanon Technology (603378.SH): Focused Fund plans to reduce its holdings by no more than 1%.
